ICHMAB20 is a monoclonal antibody that specifically targets and blocks the PD-1/PD-L1 pathway, allowing the immune system to recognize and attack melanoma cells. This approach has shown promising results in clinical trials, with some patients experiencing long-term remission and improved overall survival, Our team at BIOOCUS Biotech is dedicated to advancing the field of cancer immunotherapy, and ICHMAB20 is a testament to our commitment to developing innovative and effective treatments for patients in need. We are excited to bring this cutting-edge therapy to the market and look forward to making a positive impact in the lives of those affected by cutaneous melanoma
Please feel free to give your inquiry in the form below We will reply you in 24 hours